Mitral Valve Prolapse and Mitral Annular Disjunction

MVP: systolic displacement of one or both leaflets ≥2 mm above the annular plane in a long-axis view (EHRA 2022). Use the parasternal long axis, not the apical 4-chamber view (Moss & Adams).

Unexplained syncope or NSVT: CMR (EHRA 2022, “should”); see the table below for monitoring. No pediatric guideline covers MVP or MAD; the statements below are general.

Arrhythmic risk features: tap each one present

24-h Holter: EHRA 2022 says all patients with MVP (“should”); Kim 2025 says asymptomatic athletes with no high-risk feature need no further evaluation. The sources differ.

The lists differ by source; marking counts nothing. Use the next table for what each source advises.
FeatureListed by
EHRA 2022 high-risk features
Unexplained syncopeEHRA
NSVTEHRA; ESC 2020 and Kim 2025 list documented ventricular arrhythmia
Sustained VT, haemodynamically toleratedEHRA
EHRA 2022 phenotypic risk features
T-wave inversion in the inferior leadsEHRA, Kim 2025, ESC 2020
Repetitive polymorphic PVCsEHRA
MAD (below)EHRA, Kim 2025
Redundant leafletsEHRA
Enlarged left atrium or EF ≤50%EHRA
LGE in the papillary muscles or next to the annulusEHRA (ICD table only); ESC 2020: basal inferolateral fibrosis
PalpitationsEHRA (CMR table only)
Other lists only
Prolonged QTKim 2025, ESC 2020
Family history of sudden cardiac deathKim 2025, ESC 2020
Bileaflet prolapseESC 2020
Severe MR or LV dysfunctionKim 2025, ESC 2020
Frequent PVCs with RBBB morphologyKim 2025
How EHRA 2022 defines arrhythmic MVP and grades arrhythmia
  • Arrhythmic MVP: MVP, with or without MAD, plus frequent (≥5% PVC burden) or complex (NSVT, VT, VF) ventricular arrhythmia, and no other arrhythmic substrate (Box 2).
  • NSVT: ≥3 beats at ≥100 bpm lasting ≤30 s. Polymorphic PVCs: ≥3 distinct morphologies. Short-coupled PVC: coupling interval <350 ms (Table 2).
  • High-risk arrhythmia: sustained VT not from an outflow tract, spontaneous polymorphic NSVT, monomorphic NSVT >180 bpm. Intermediate: polymorphic PVCs, monomorphic NSVT <180 bpm, bigeminy or couplets. Low: frequent PVCs without complex arrhythmia or morphological high-risk features.
  • Adult Table 3, one adult cohort: severe arrhythmia (VT runs ≥180 bpm or sustained VT or VF) mortality HR 2.94 (1.36–6.36).
  • In most asymptomatic patients, infrequent simple ectopy (<5% single PVCs) on Holter may need nothing further.

What the sources advise

EHRA 2022 consensus: “should” (green heart) or “may” (yellow heart); Kim 2025 Table 7 gives no class
StrengthRecommendationSource
ShouldHistory (syncope, family history of sudden cardiac death), examination, 12-lead ECG, echo, 24-h Holter in every patient with MVPEHRA text, Tables 4–6
ShouldCMR in unexplained syncope and/or NSVTEHRA Table 8
ShouldAMVP: exercise test for adrenergic arrhythmiaEHRA Table 9
MayAMVP with ≥1 phenotypic feature: CMREHRA Table 8
MayImplantable loop recorder: unexplained syncope with non-revealing monitoring; AMVP with high-risk features and negative CMR; AMVP with ≥1 phenotypic feature and LGEEHRA Table 6
No classAthletes: no high-risk feature, no further evaluation and may compete; high-risk feature, exercise test, ambulatory monitoring and CMR; arrhythmic MVP, expert assessment and ICD risk stratificationKim 2025 Table 7
ShouldICD after VF or poorly tolerated VT with no reversible causeEHRA Table 11
MayICD: AMVP with unexplained syncope and sustained VT or NSVT likely from the mitral apparatus; AMVP with 1 high-risk and ≥2 phenotypic featuresEHRA Table 11
ShouldPVC ablation if frequent PVCs with symptoms or reduced LV function, in an experienced centreEHRA Table 12
More EHRA 2022 statements
  • “Should”: MVP with complex ectopy (for example fast NSVT) followed closely; CMR before a secondary-prevention ICD without delaying it; CMR when echo cannot assess the ventricles or structure; echo in suspected AMVP measures leaflet length and thickness, annulus, MAD and MR; treat suspected PVC-induced cardiomyopathy; ICD with LVEF <35% and symptomatic heart failure despite ≥3 months of medical therapy.
  • “Should”, also: structured risk stratification for every patient with MVP; periodic clinical re-evaluation, or when syncope or palpitations appear; in the work-up of frequent PVCs, syncope or aborted arrest with no other cause, look at the mitral valve and annulus.
  • “May”: Holter up to 7 days in selected cases; periodic Holter and echo in AMVP follow-up; exercise test before sport; mitral surgery may lower malignant arrhythmia in severe MR.
  • Not endorsed: electrophysiology study with programmed stimulation. Genetic testing: suggested in syndromic MVP, not justified in non-syndromic MVP.

Mitral regurgitation: follow-up and surgery

Adult ACC/AHA 2020 Tables 5, 17 and §7.2.4; adolescents follow the adult MR indications (Moss & Adams). Grade MR on Valve Regurgitation.
StageEchoNext
No or mild MRChild, asymptomatic: every 2–5 y (Moss & Adams, textbook). Adult, mild: every 3–5 yReassure; encourage exercise (Moss & Adams)
Moderate MRAdult: every 1–2 y. Child: more often than 2–5 y (Moss & Adams)Follow
Severe, asymptomatic, LVEF >60% and LVESD <40 mm (C1)Every 6–12 mo; more often if the LV is dilatingRepair reasonable at a valve centre if >95% likely durable and mortality <1% (class IIa); surgery may be considered if LV size rises or EF falls on ≥3 studies (class IIb)
Severe, asymptomatic, LVEF ≤60% and/or LVESD ≥40 mm (C2)–Surgery (class I)
Severe, symptomatic (D)–Intervention whatever the LV function (class I)
ACC/AHA 2020 recommendations with class and level
Adult ACC/AHA 2020 §7.2.3, §7.2.4, chronic primary MR
ClassRecommendationLOE
ISymptomatic severe MR (D): mitral intervention irrespective of LV systolic functionB-NR
IAsymptomatic severe MR with LVEF ≤60% or LVESD ≥40 mm (C2): surgeryB-NR
IDegenerative MR: repair rather than replacement when a successful, durable repair is possibleB-NR
IIaAsymptomatic severe MR, LVEF ≥60% and LVESD ≤40 mm (C1): repair if >95% likely durable without residual MR and expected mortality <1%, at a Primary or Comprehensive Valve CenterB-NR
IIbC1 (LVEF >60% and LVESD <40 mm) with progressive LV enlargement or falling EF on ≥3 studies: surgery may be consideredC-LD
III: HarmDisease limited to less than half the posterior leaflet: no replacement unless repair was attempted at a Primary or Comprehensive Valve Center and failedB-NR
III: No benefitVasodilators in asymptomatic primary MR with normal LV function and normal blood pressureB-NR

ACC/AHA 2020 prints C1 as LVEF ≥60% and LVESD ≤40 mm in one recommendation and >60% and <40 mm in the next, in Table 17 and in Figure 8. Severe MR: vena contracta ≥0.7 cm, regurgitant volume ≥60 mL, regurgitant fraction ≥50%, ERO ≥0.40 cm² (Figure 8). Moss & Adams: anterior-leaflet repair carries a higher reoperation risk than posterior; repair in experienced centres. The 2025 ESC/EACTS recommendations are not shown.

Mitral annular disjunction (MAD)

Studies by population: prevalence, growth and outcome
Studies, by population (full texts read)
PopulationFinding
Children Marfan, <21 y, n=185MAD (≥2 mm) in 60%, from the neonatal period; in 90% of those with MVP; grows 0.18 mm a year but is constant indexed to height; echo and CMR agree (kappa 0.89). Outcomes not studied (Doan 2024)
Children Healthy controls, CMR, 14 ± 3 y, n=30Largest MAD 3.6 mm (Castellanos 2025)
Children and young adults, connective tissue disorders, CMR, 17 ± 6 y, n=254Height-indexed maximum systolic MAD ≥0.033 mm/cm: events 18.6% vs 2.6% below it (AUC 0.74); events were mostly deaths (Castellanos 2025)
Marfan and Loeys-Dietz, echo, n=168MAD in 41%, at all ages; more mitral events and earlier aortic events with MAD (Chivulescu 2021)
Heritable thoracic aortic disease, echoMAD commoner with SMAD3 variants; MAD >10 mm only with TGF-β pathway variants; MAD not independently linked to events (Asokan 2024)
Adult General population, CMR, n=2607Some disjunction in 76%, mostly anterior and inferior walls; inferolateral in 5%; authors call only extensive inferolateral MAD worth work-up (Zugwitz 2022)
Adult MVP cohortsMAD in 20–58%; linked to arrhythmia during follow-up but not to excess death within 10 years (EHRA 2022, citing cohorts)
Adult Arrhythmic MVP with a loop recorder, n=60Severe arrhythmia 4% per person-year; longer posterolateral MAD among the predictors (Aabel 2023)
Adult Idiopathic VF, CMR, n=72Inferolateral MAD 11% vs 1% of matched controls, some without MVP (Groeneveld 2022)

Sports

ESC 2020 sports cardiology
  • ESC 2020 §5.3.5.1 (text, no recommendation table): exercise test and 24-hour ECG for individuals with MVP; CMR if inferior T-wave inversion or LV-origin ventricular ectopy. Mild or moderate MR without risk markers: all competitive and leisure sports.
  • Adult Asymptomatic severe MR without high-risk markers: low- to moderate-intensity sport if LVEDD <60 mm (or <35.5 mm/m² men, <40 mm/m² women), LVEF ≥60%, resting sPAP <50 mmHg and a normal exercise test.
  • Symptomatic with any high-risk feature: no recreational or competitive sport; low-intensity aerobic exercise encouraged.

Syndromes, family and endocarditis

Outcome

Sudden death and other adult numbers
  • Adult EHRA 2022, citing cohorts: sudden death 0.2–0.4% a year; 1.8% a year with severe MR from a flail leaflet; 0.14% in a community population; MVP in 4–7% of young sudden-death victims (13% of women).
  • Adult ESC 2020 sports: prevalence 1–2.4%; severe MR in 5–10%; 7% of 650 young-adult sudden deaths in an Italian registry; 7449 young competitive athletes, MVP 2.9%, no deaths over 8 ± 2 y, adverse events 0.5% a year.
  • Adult Framingham Offspring, 63 with MVP: 17% reached at least moderate MR and 8% had repair over 3–16 years (Delling 2016).

Diagnosis, arrhythmic risk features, mitral regurgitation, MAD, sports and outcome

Key points

Sources and how this page was checked

Full text read

Textbook

How it was checked

Not covered on this page